

# **2023-2027 Singapore Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers-Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers**

<https://marketpublishers.com/r/2041DCD3E6E0EN.html>

Date: September 2023

Pages: 0

Price: US\$ 2,000.00 (Single User License)

ID: 2041DCD3E6E0EN

## **Abstracts**

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report is available by section, and can be customized to specific information needs and budget. The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

### Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the

rapid market expansion.

## Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

## Instrumentation Review

Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

## Technology Review

Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

## Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. Partial Table of Contents

Introduction

Market Overview

Major Product Development Opportunities

Design Criteria for New Products

Alternative Market Penetration Strategies

Potential Market Entry Barriers and Risks

Major Current and Emerging Diagnostic Tests

Instrumentation Review and Market Needs

Current and Emerging Technologies

Market Size, Supplier Shares, Test Volume and Sales Segment Forecasts

Competitive Profiles and Strategies

## Contents

### I. INTRODUCTION

### II. MARKET OVERVIEW

### III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

### IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

### V. ALTERNATIVE MARKET PENETRATION STRATEGIES

### VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

### VII. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS

1. Introduction
2. Cancer Diagnostic Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembryonic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood

18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Cancer Diagnostics
27. Oncogenes
  - &nbsp;&nbsp;&nbsp;Abl/abl-bcr
  - &nbsp;&nbsp;&nbsp;AIB1
  - &nbsp;&nbsp;&nbsp;BCL-2
  - &nbsp;&nbsp;&nbsp;BRCA1
  - &nbsp;&nbsp;&nbsp;CD44
  - &nbsp;&nbsp;&nbsp;C-fos
  - &nbsp;&nbsp;&nbsp;C-myb
  - &nbsp;&nbsp;&nbsp;C-myc
  - &nbsp;&nbsp;&nbsp;CYP-17
  - &nbsp;&nbsp;&nbsp;Erb-B
  - &nbsp;&nbsp;&nbsp;HPC1
  - &nbsp;&nbsp;&nbsp;N-myc
  - &nbsp;&nbsp;&nbsp;P40
  - &nbsp;&nbsp;&nbsp;P51
  - &nbsp;&nbsp;&nbsp;P53
  - &nbsp;&nbsp;&nbsp;PIK3CA
  - &nbsp;&nbsp;&nbsp;PTI-1
  - &nbsp;&nbsp;&nbsp;Ras
  - &nbsp;&nbsp;&nbsp;Reg
  - &nbsp;&nbsp;&nbsp;Sis
  - &nbsp;&nbsp;&nbsp;Src and others
28. Polypeptide Growth Factors
  - &nbsp;&nbsp;&nbsp;Basic Fibroblast Growth Factor
  - &nbsp;&nbsp;&nbsp;Beta-TGF
  - &nbsp;&nbsp;&nbsp;Cachectin (TNT)
  - &nbsp;&nbsp;&nbsp;Calmodulin
  - &nbsp;&nbsp;&nbsp;ECFR
  - &nbsp;&nbsp;&nbsp;Nerve Growth Factor (NGF)
  - &nbsp;&nbsp;&nbsp;Epidermal Growth Factor (EGF)

&nbsp;&nbsp;&nbsp;Ornithine Decarboxylase  
&nbsp;&nbsp;&nbsp;Transferrin  
&nbsp;&nbsp;&nbsp;Transforming Growth Factor-Alpha  
29. Ectopic Hormones  
30. Colony Stimulating Factors  
31. Lymphokines  
&nbsp;&nbsp;&nbsp;Alpha-Interferon  
&nbsp;&nbsp;&nbsp;B Cell Growth Factors  
&nbsp;&nbsp;&nbsp;B Cell Growth Factor (BCGF)  
&nbsp;&nbsp;&nbsp;Gamma-Interferon  
&nbsp;&nbsp;&nbsp;Interleukin-1 (IL-1)  
&nbsp;&nbsp;&nbsp;Macrophage Activating Factor  
32. Immunohistochemical Stains  
33. Emerging Cancer Diagnostics  
&nbsp;&nbsp;&nbsp;N-Acetylglucosamine  
&nbsp;&nbsp;&nbsp;Actin  
&nbsp;&nbsp;&nbsp;Alpha-Actin  
&nbsp;&nbsp;&nbsp;Antineuronal Antibodies  
&nbsp;&nbsp;&nbsp;7B2  
&nbsp;&nbsp;&nbsp;B72.3  
&nbsp;&nbsp;&nbsp;Bax  
 &nbsp;&nbsp;BCD-F9  
&nbsp;&nbsp;&nbsp;BLCA-4  
&nbsp;&nbsp;&nbsp;Blood Group Antigens A,B,H  
&nbsp;&nbsp;&nbsp;CA  
&nbsp;&nbsp;&nbsp;CA 72-4/TAG-72  
&nbsp;&nbsp;&nbsp;CA  
&nbsp;&nbsp;&nbsp;CA-242  
&nbsp;&nbsp;&nbsp;CA-549  
&nbsp;&nbsp;&nbsp;CAM  
&nbsp;&nbsp;&nbsp;CAR-3  
&nbsp;&nbsp;&nbsp;Cathepsin-D  
&nbsp;&nbsp;&nbsp;Chromogranin A and B  
&nbsp;&nbsp;&nbsp;Cluster 1 Antigen  
&nbsp;&nbsp;&nbsp;Cluster-5/5A Antigen  
&nbsp;&nbsp;&nbsp;CTA  
&nbsp;&nbsp;&nbsp;CU18  
&nbsp;&nbsp;&nbsp;DR-70  
&nbsp;&nbsp;&nbsp;DU-PAN-2

&nbsp;&nbsp;&nbsp;Endometrial Bleeding Associated Factor  
&nbsp;&nbsp;&nbsp;Endostatin  
&nbsp;&nbsp;&nbsp;Epithelial Membrane Antigen  
&nbsp;&nbsp;&nbsp;Feulgen Hydrolysis  
&nbsp;&nbsp;&nbsp;Fibronectin  
&nbsp;&nbsp;&nbsp;FSH  
&nbsp;&nbsp;&nbsp;(1-\$\$\$3)-L-fucosyltransferase  
&nbsp;&nbsp;&nbsp;Gastrin-Releasing Peptide (GRP)  
&nbsp;&nbsp;&nbsp;GDCFP-15  
&nbsp;&nbsp;&nbsp;Glucagon  
&nbsp;&nbsp;&nbsp;Glycoamines  
&nbsp;&nbsp;&nbsp;H23  
&nbsp;&nbsp;&nbsp;Her-2  
&nbsp;&nbsp;&nbsp;Human Carcinoma Antigen  
&nbsp;&nbsp;&nbsp;HPA  
&nbsp;&nbsp;&nbsp;HSP27  
&nbsp;&nbsp;&nbsp;Intermediate Filaments  
&nbsp;&nbsp;&nbsp;Cytokeratins/CK18/Cyfra 21-1  
&nbsp;&nbsp;&nbsp;Desmin  
&nbsp;&nbsp;&nbsp;Gliofibrillary Acid Protein  
&nbsp;&nbsp;&nbsp;Neurofilaments  
&nbsp;&nbsp;&nbsp;Vimentin  
&nbsp;&nbsp;&nbsp;KA  
&nbsp;&nbsp;&nbsp;Kinases  
&nbsp;&nbsp;&nbsp;KP16D3  
&nbsp;&nbsp;&nbsp;LAI  
&nbsp;&nbsp;&nbsp;Leukocyte Common Antigen  
&nbsp;&nbsp;&nbsp;Lewis Antigens  
&nbsp;&nbsp;&nbsp;Lysophosphatidic Acid (LPA)  
&nbsp;&nbsp;&nbsp;Ma 695/Ma  
&nbsp;&nbsp;&nbsp;MABDF3  
&nbsp;&nbsp;&nbsp;MAG  
&nbsp;&nbsp;&nbsp;ME1  
&nbsp;&nbsp;&nbsp;Minactivin  
&nbsp;&nbsp;&nbsp;MN/CA9  
&nbsp;&nbsp;&nbsp;MSA  
&nbsp;&nbsp;&nbsp;Mucin Cancer Antigen (MCA)  
&nbsp;&nbsp;&nbsp;Multiple Tumor Suppressor  
&nbsp;&nbsp;&nbsp;Myosin

&nbsp;&nbsp;&nbsp;NEA-130  
&nbsp;&nbsp;&nbsp;NMP22  
&nbsp;&nbsp;&nbsp;OA-519  
&nbsp;&nbsp;&nbsp;Opiod Peptides  
&nbsp;&nbsp;&nbsp;P-glycoprotein  
&nbsp;&nbsp;&nbsp;Pancreatic Oncofetal Antigen (POA)  
&nbsp;&nbsp;&nbsp;Placental Lactogen  
&nbsp;&nbsp;&nbsp;PR92  
&nbsp;&nbsp;&nbsp;Proliferative Index, Ki-67  
&nbsp;&nbsp;&nbsp;Px  
&nbsp;&nbsp;&nbsp;RB Inactivation/Deletion  
&nbsp;&nbsp;&nbsp;Ret  
&nbsp;&nbsp;&nbsp;SCCL  
&nbsp;&nbsp;&nbsp;Selectin  
&nbsp;&nbsp;&nbsp;Sialic Acid  
&nbsp;&nbsp;&nbsp;Sialyl SSEA-1/SLX  
&nbsp;&nbsp;&nbsp;SN10  
&nbsp;&nbsp;&nbsp;Somatostatin  
&nbsp;&nbsp;&nbsp;TA-90  
&nbsp;&nbsp;&nbsp;TABA  
&nbsp;&nbsp;&nbsp;Tachykinin  
&nbsp;&nbsp;&nbsp;TAG  
&nbsp;&nbsp;&nbsp;TPS  
&nbsp;&nbsp;&nbsp;Troponin  
&nbsp;&nbsp;&nbsp;Tubulin  
&nbsp;&nbsp;&nbsp;VCAM  
&nbsp;&nbsp;&nbsp;VEGF  
&nbsp;&nbsp;&nbsp;Villen and others

## **VIII. INSTRUMENTATION REVIEW AND MARKET NEEDS**

## **IX. CURRENT AND EMERGING TECHNOLOGIES**

1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
  - a. Chronic Myelogenous Leukemia (CML)



- b. Acute Myeloid Leukemia (AML)
- c. Acute Lymphoblastic Leukemia (ALL)
- d. Malignant Lymphomas Lymphoid Malignancies
- e. Chronic Lymphocytic Leukemia (CLL)
- f. Solid Cancers
- g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies

## **X. MARKET SIZE, TEST VOLUME AND SALES FORECASTS**

## **XI. COMPETITIVE PROFILES**

The report provides strategic assessments of over 30 leading cancer diagnostics market players and

start-up companies with innovative technologies and products, including:

- &nbsp;&nbsp; Abbott
- &nbsp;&nbsp; Affymetrix
- &nbsp;&nbsp; Beckman Coulter/Danaher/Cepheid
- &nbsp;&nbsp; Becton Dickinson
- &nbsp;&nbsp; bioMerieux
- &nbsp;&nbsp; Bio-Rad
- &nbsp;&nbsp; DiaSorin
- &nbsp;&nbsp; Eiken Chemical
- &nbsp;&nbsp; Elitech Group
- &nbsp;&nbsp; Enzo Biochem
- &nbsp;&nbsp; Fuifilm Wako
- &nbsp;&nbsp; Fujirebio
- &nbsp;&nbsp; Grifols
- &nbsp;&nbsp; Hologic
- &nbsp;&nbsp; Leica Biosystems
- &nbsp;&nbsp; PerkinElmer
- &nbsp;&nbsp; Qiagen
- &nbsp;&nbsp; QuidelOrtho
- &nbsp;&nbsp; Roche

&nbsp;&nbsp; Siemens Healthineers  
&nbsp;&nbsp; Takara Bio  
&nbsp;&nbsp; Thermo Fisher and others.

## List Of Tables

### LIST OF TABLES

Cancer Diagnostic Test Volume and Sales Forecasts  
Cancer Diagnostic Volume Forecast by Test  
Cancer Diagnostics Sales Forecast by Test  
ACTH Test Volume and Diagnostics Sales Forecast  
AFP Test Volume and Diagnostics Sales Forecast  
Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast  
CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast  
CA 19-9 Test Volume and Diagnostics Sales Forecast  
CA-125 Test Volume and Diagnostics Sales Forecast  
Calcitonin Test Volume and Diagnostics Sales Forecast  
Cathepsin Test Volume and Diagnostics Sales Forecast  
CEA Test Volume and Diagnostics Sales Forecast  
Chromogranin Test Volume and Diagnostics Sales Forecast  
Colon-specific Antigen Test Volume and Diagnostics Sales Forecast  
Cytokeratins Test Volume and Diagnostics Sales Forecast  
Estrogen Receptor Test Volume and Diagnostics Sales Forecast  
Ferritin Test Volume and Diagnostics Sales Forecast  
Gastrin Test Volume and Diagnostics Sales Forecast  
HCG Test Volume and Diagnostics Sales Forecast  
Insulin Test Volume and Diagnostics Sales Forecast  
Interferons Test Volume and Diagnostics Sales  
Interleukins Test Volume and Diagnostics Sales Forecast  
Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast  
NSE Test Volume and Diagnostics Sales Forecast  
Nucleolar Test Volume and Diagnostics Sales Forecast  
Occult Blood Test Volume and Diagnostics Sales Forecast  
Oncogenes Test Volume and Diagnostics Sales Forecast  
Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast  
PAP Smear Test Volume and Diagnostics Sales Forecast Parathyroid  
Hormone Test Volume and Diagnostics Sales Forecast Progesterone  
Receptor Test Volume and Diagnostics Sales Forecast PAP Test  
Volume and Diagnostics Sales Forecast  
PSA Test Volume and Diagnostics Sales Forecast  
S-100 Protein Test Volume and Diagnostics Sales Forecast  
Serotonin Test Volume and Diagnostics Sales Forecast

Sialic Acid Test Volume and Diagnostics Sales Forecast  
Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast  
TDT Test Volume and Diagnostics Sales Forecast  
Thymidine Kinase Test Volume and Diagnostics Sales Forecast  
Thyroglobulin Test Volume and Diagnostics Sales Forecast  
TPA Test Volume and Diagnostics Sales Forecast  
Cancer Diagnostic Classification  
Major Companies Developing or Marketing ACTH Tests  
Major Companies Developing or Marketing AFP Tests  
Major Companies Developing or Marketing Beta-2 Microglobulin Tests  
Major Companies Developing or Marketing CA 15-3/27.29 Tests  
Major Companies Developing or Marketing CA 19-9 Tests  
Major Companies Developing or Marketing CA 125 Tests  
Major Companies Developing or Marketing Calcitonin Tests  
Major Companies Developing or Marketing CEA Tests  
Major Companies Developing or Marketing Estrogen Receptor Tests  
Major Companies Developing or Marketing Progesterone Receptor Tests  
Major Companies Developing or Marketing Ferritin Tests  
Major Companies Developing or Marketing Gastrin Tests  
Major Companies Developing or Marketing HCG Tests  
Major Companies Developing or Marketing Insulin Tests  
Major Companies Developing or Marketing NSE Tests  
Major Companies Developing or Marketing Occult Blood Tests  
Major Companies Developing or Marketing PAP Smear/HPV Tests  
Major Companies Developing or Marketing PAP Tests  
Major Companies Developing or Marketing PSA Tests  
Major Companies Developing or Marketing Lymphocyte Sub-classification Tests  
Biochemical Markers Potential Applications in Cancer Diagnosis  
Oncogenes Potential Applications in Cancer Diagnosis  
Major Companies Developing or Marketing Oncogene Tests  
Growth Factors Potential Applications in Cancer Diagnosis  
Colony Stimulating Factors Potential Applications in Cancer Diagnosis  
Lymphokines Potential Applications in Cancer Diagnosis  
Immunohistochemical Stains Potential Applications in Cancer Diagnosis

## I would like to order

Product name: 2023-2027 Singapore Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers-Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

Product link: <https://marketpublishers.com/r/2041DCD3E6E0EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2041DCD3E6E0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970